56例抗肿瘤药物致肝损伤临床特点分析

张惠娟; 史祖宣; 赵兰芳; 高天慧; 李健

doi:10.3969/j.issn.1001-5256.2019.03.024

56例抗肿瘤药物致肝损伤临床特点分析

DOI: 10.3969/j.issn.1001-5256.2019.03.024

1. 海南医学院第一附属医院医疗保健科
2. 河南省人民医院肿瘤内科
3. 河南省人民医院消化内科

基金项目:

河南省科技攻关项目(172102310370)；

详细信息

中图分类号: R575;R730.5
计量
- 文章访问数: 1716
- HTML全文浏览量: 71
- PDF下载量: 350
- 被引次数: 0
出版历程
- 出版日期: 2019-03-20

Clinical features of liver injury induced by antitumor drugs:An analysis of 56 cases

Department of Medical Care, The First Affiliated Hospital of Hainan Medical College

Research funding:

摘要

摘要:
目的分析恶性肿瘤治疗过程中抗肿瘤药物所致药物性肝损伤（DILI）的临床特点。方法回顾性分析河南省人民医院2015年1月-2016年12月确诊为恶性肿瘤且在抗肿瘤药物治疗期间出现DILI的56例患者的临床资料,包括性别、年龄、原发肿瘤类型、嗜肝病毒感染情况、肝功能、化疗药物种类、肝损伤发生时间、保肝药物应用情况及治疗后肝损伤转归等。结果 56例抗肿瘤药物所致DILI中,临床分型以肝细胞损伤型为主（30例,53. 6%）,损伤程度以轻度肝损伤为主（80. 4%,45/56）。以FOLFOX方案、GP/DP方案和CHOP方案多见,多药联合引起DILI比较高（89. 3%,50/56）,常见药物为铂类、影响微管蛋白药物和烷化剂。DILI多发生在用药后1～2周之内（62. 5%,35/56）。结论 DILI以轻度、肝细胞损伤型为主,主要发生在用药后1～2周内,以铂类抗肿瘤药物及相关化疗方案最常见,多种抗肿瘤药物联合应用更易发生DILI,DILI预后良好。
- 抗肿瘤药 /
- 药物性肝损伤
Abstract:
Objective To investigate the clinical features of drug-induced liver injury ( DILI) caused by antitumor drugs during the treat-ment of malignant tumors. Methods A retrospective analysis was performed for the clinical data of 56 patients who were diagnosed with ma-lignant tumors in Henan Provincial People's Hospital from January 2015 to December 2016 and experienced DILI during the treatment withantitumor drugs, including sex, age, type of primary tumor, hepatotropic virus infection, liver function, type of chemotherapeutics, onsettime of liver injury, application of liver-protecting drugs, and outcome of liver injury. Results Among the 56 patients with DILI caused byantitumor drugs, 30 ( 53. 6%) had hepatocellular injury, and 45 ( 80. 4%) had mild liver injury. FOLFOX, GP/DP, and CHOP were themost common regimens for DILI, and of all 56 patients, 50 ( 89. 3%) had DILI caused by multiple drugs. Platinum-based drugs, anti-microtubule agents, and alkylating agents were the common drugs causing DILI. Of all 56 patients, 35 ( 62. 5%) developed DILI within 1-2 weeks after medication. Conclusion DILI caused by antitumor drugs mainly has a mild degree and hepatocellular injury type is the mostcommon clinical type. Platinum-based antitumor drugs and related chemotherapeutic regimens are the most common drugs for DILI. A com-bination of multiple antitumor drugs is more likely to cause DILI, and patients with such DILI often have a good prognosis.
- antineoplastic agents /
- drug-induced liver injury

HTML全文

参考文献(28)

[1] CHEN W, ZHENG R, ZUO T, et al. National cancer incidenceand mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28 (1) :1-11.

[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in Chi-na, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.

[3] REN J, ZHOU XN. Development of drug induced liver injury inanti-tumor treatment[J]. Chin J Drug Appl Monit, 2012, 9 (6) :309-313. (in Chinese) 任军, 周心娜.抗肿瘤药物肝损伤研究进展[J].中国药物应用与监测, 2012, 9 (6) :309-313.

[4] VINCENZI B, ARMENTO G, SPALATO CERUSO M, et al, Drug-induced hepatotoxicity in cancer patients-implication for treat-ment[J]. Expert Opin Drug Saf, 2016, 15 (9) :1219-1238.

[5] Drug-induced Liver Disease Study Group, Chinese Society ofHepatology, Chinese Medical Association. Guidelines for themanagement of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[6] CHEN CW. Research advances in drug-induced liver injuryand existing problems in China[J]. J Clin Hepatol, 2018, 34 (6) :1147-1151. (in Chinese) 陈成伟.药物性肝损伤的研究进展及我国存在的问题[J].临床肝胆病杂志, 2018, 34 (6) :1147-1151.

[7] SHEN T, HUANG X, WANG YY, et al. Current status of epide-miological study on drug-induced liver injury in China[J]. JClin Hepatol, 2018, 34 (6) :1152-1155. (in Chinese) 沈弢, 黄昕, 王誉雅, 等.我国药物性肝损伤流行病学研究现状[J].临床肝胆病杂志, 2018, 34 (6) :1152-1155.

[8] YUAN Y, LI J, LAN L, et al. Analysis of clinical characteristicsamong 245 cases of patients with drug-induced liver damage[J]. Chronic Pathematology J, 2015, 16 (2) :170-172. (inChinese) 袁媛, 李健, 兰玲, 等. 245例药物性肝损伤病例的临床流行病学特征描述[J].慢性病学杂志, 2015, 16 (2) :170-172.

[9] ZHU CW, WANG HN, YUAN JL, et al. Clinical features of drug-induced liver injury:An analysis of 445 cases[J]. J Clin Hepatol, 2018, 34 (2) :354-358. (in Chinese) 朱春雾, 王海南, 袁继丽, 等. 445例药物性肝损伤的临床分析[J].临床肝胆病杂志, 2018, 34 (2) :354-358.

[10] THATISHETTY AV, AGRESTI N, O'BRIEN CB. Chemotherapy-induced hepatotoxicity[J]. Clin Liver Dis, 2013, 17 (4) :671-686.

[11] BAHIRWANI R, REDDY KR. Drug-induced liver injury due tocancer chemotherapeutic agents[J]. Semin Liver Dis, 2014, 34 (2) :162-171.

[12] LEISE MD, POTERUCHA JJ, TALWALKAR JA. Drug-inducedliver injury[J]. Mayo Clin Proc, 2014, 89 (1) :95-106.

[13] YAN SY, FAN JG. Effect of antineoplastic drugs on liver andtheir application in patients with liver diseases[J]. World ClinDrugs, 2011, 32 (9) :513-517. (in Chinese) 颜士岩, 范建高.抗肿瘤药物对肝脏的影响及其在肝病患者中的应用[J].世界临床药物, 2011, 32 (9) :513-517.

[14] HU XY, SUN J, PENG J. New considerations in antiviral thera-py for special populations with chronic hepatitis B[J]. J ClinHepatol, 2016, 32 (11) :2054-2057. (in Chinese) 胡晓云, 孙剑, 彭劼.乙型肝炎特殊人群抗病毒治疗的新认识[J].临床肝胆病杂志, 2016, 32 (11) :2054-2057.

[15] KIM E, YUNE S, HA JM, et al. Hepatitis B virus reactivation dur-ing anticancer chemotherapy in patients with past hepatitis B virusinfection[J]. Hepatogastroenterology, 2014, 61 (134) :1704-1711.

[16] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinicalpractice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int, 2016, 10 (1) :1-98.

[17] WU SX, XU HY, HUANG HC, et al. Clinical analysis of liver in-jury and hepatitis B virus reactivation after chemotherapy inHBsAg-positive patients with malignant tumors[J]. J ClinHepatol, 2016, 32 (1) :110-113. (in Chinese) 吴盛喜, 许鸿鹞, 黄河澄, 等. HBsAg阳性恶性肿瘤患者化疗后肝损伤及HBV再激活的临床分析[J].临床肝胆病杂志, 2016, 32 (1) :110-113.

[18] XU L, TU Z, XU G, et al. Epirubicin directly promotes hepati-tis B virus (HBV) replication in stable HBV-expressing celllines:A novel mechanism of HBV reactivation following anti-cancer chemotherapy[J]. Mol Med Rep, 2014, 9 (4) :1345-1350.

[19] SANAGAWA A, HOTTA Y, KATAOKA T, et al. Hepatitis B in-fection reported with cancer chemotherapy:Analyzing the USFDA adverse event reporting system[J]. Cancer Med, 2018, 7 (6) :2269-2279.

[20] YANG LH, LIU R, ZENG QY, et al. Association of methyle-netetrahydrofolate reductase gene polymorphism in childrenwith acute lymphoblastic leukemia and adverse reaction ofhigh dose methotrexate[J]. J Appl Clin Pediatr, 2012, 27 (6) :440-442. (in Chinese) 杨丽华, 刘茹, 曾其毅, 等.急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶基因多态性与大剂量甲氨蝶呤不良反应的相关性[J].实用儿科临床杂志, 2012, 27 (6) :440-442.

[21] SCRIPTURE CD, FIGG WD. Drug interactions in cancer thera-py[J]. Nat Rev Cancer, 2006, 6 (7) :546-558.

[22] CAMPEN CJ, VOGEL WH, SHAH PJ. Managing drug interac-tions in cancer therapy:A guide for the advanced practitioner[J]. J Adv Pract Oncol, 2017, 8 (6) :609-620.

[23] TEO YL, HO HK, CHAN A. Formation of reactive metabolitesand management of tyrosine kinase inhibitor-induced hepato-toxicity:A literature review[J]. Expert Opin Drug Metab Toxi-col, 2015, 11 (2) :231-242.

[24] LOU XE, CHEN M, YANG B. Research progress in toxicologyof molecular targeted anticancer drugs[J]. J Zhejiang Univ:Med Sci, 2015, 44 (5) :473-478. (in Chinese) 娄小娥, 陈敏, 杨波.分子靶向抗肿瘤药物的毒性研究进展[J].浙江大学学报:医学版, 2015, 44 (5) :473-478.

[25] PAECH F, BOUITBIR J, KRHENBHL S. Hepatocellular tox-icity associated with tyrosine kinase inhibitors:Mitochondrialdamage and inhibition of glycolysis[J]. Front Pharmacol, 2017, 8:367.

[26] SHAH RR, MORGANROTH J, SHAH DR. Hepatotoxicity of tyro-sine kinase inhibitors:Clinical and regulatory perspectives[J].Drug Saf, 2013, 36 (7) :491-503.

[27] Chinese Society of Infectious Diseases, Chinese Medical As-sociation, Expert Committee for Prevention and Managementof Liver Inflammation. Prevention and management of liver in-flammation:An expert consensus in China[J]. Chin J Clin In-fect Dis, 2014, 7 (1) :4-12. (in Chinese) 中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会.肝脏炎症及其防治专家共识[J].中华临床感染病杂志, 2014, 7 (1) :4-12.

[28] SUN YJ, QI WX, YAO Y. Prevention and treatment of glutathi-one in chemotherapy-induced liver injury[J]. China Cancer, 2015, 24 (1) :57-63. (in Chinese) 孙元珏, 祁伟祥, 姚阳.还原型谷胱甘肽与肿瘤化疗相关性肝损伤的防治[J].中国肿瘤, 2015, 24 (1) :57-63.

施引文献

资源附件(0)

访问统计